Stock Groups

Pfizer seeks FDA clearance for COVID-19 vaccine in younger children By Reuters

© Reuters. FILEPHOTO: This illustration, taken October 30, 2020 shows a woman holding a small plastic bottle with the “Coronavirus CoVID-19 Vaccine” sticker. She also holds a medical pen and an instruction manual. REUTERS/Dado Ruvic

(Reuters) – Pfizer Inc (NYSE:) and BioNTech SE (NASDAQ:) on Tuesday asked U.S. health regulators to authorize their COVID-19 vaccine in kids aged 5 to 11.

According to data from American Academy of Pediatrics, COVID-19 infection rates have increased in children and reached their peak in September. The U.S. Food and Drug Administration has been asked to approve the application.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. Instead, they are determined by marketmakers. As such, the prices might not reflect market conditions and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.